Ari Pelcovits, MD
Internal Medicine · Providence, RINPI 1679951156
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Genmab U.S., Inc. accounts for 88.9% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $3,112, more than ten times the $193 reported in 2019. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $332.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$3K
- ADC Therapeutics America, Inc.$176
- Jazz Pharmaceuticals Inc.$127
- Foundation Medicine, Inc.$66
Across 24 payments — averaging $7309.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$175K
What the payments were for
- Consulting fees$1,70651%
- Travel & lodging$1,10433%
- Food & beverage$51716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 6 | $2,958 |
| ADC Therapeutics America, Inc. | 2 | $176 |
| Jazz Pharmaceuticals Inc. | 1 | $127 |
| Foundation Medicine, Inc. | 1 | $66 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,328 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 112 | $1,466,903 |
| RevlimidLenalidomide | 84 | $1,417,678 |
| PomalystPomalidomide | 55 | $1,233,965 |
| CalquenceAcalabrutinib Maleate | 29 | $364,964 |
| BrukinsaZanubrutinib | 23 | $320,453 |
| EliquisApixaban | 56 | $33,488 |
| Anagrelide Hcl | 11 | $1,234 |
| Hydroxyurea | 21 | $615 |
| Dexamethasone | 38 | $555 |
| Acyclovir | 52 | $448 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 34 | $324 |
| Klor-Con M20Potassium Chloride | 16 | $224 |
| Prednisone | 35 | $86 |
| Ondansetron Hcl | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Providence
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Brian McCauleyProvidence$20K
- Meghan NahassProvidence$19K
- William LangProvidence$15K
- Abdelmoniem MoustafaProvidence$13K
- Khushal ChoudharyProvidence$10K
- Kenneth ChenProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.